Premium
Ertugliflozin: a new SGLT2 inhibitor for type 2 diabetes
Author(s) -
Chaplin Steve
Publication year - 2019
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1798
Subject(s) - medicine , type 2 diabetes , adverse effect , diabetes mellitus , transporter , pharmacology , endocrinology , biochemistry , chemistry , gene
Ertugliflozin (Steglatro) is a new sodiumglucose co‐transporter‐2 (SGLT2) inhibitor for the treatment of adults with type 2 diabetes. This article examines its place in therapy, clinical trial efficacy and adverse effects.